Therapeutic Goods (Standards for Biologicals—General and Specific Requirements) (TGO 109) Order 2021

TGO 109 organises its requirements around a set of recurring regulatory concepts. Understanding these concepts is essential for applying the instrument and for identifying where judgement, validation and documentation are required.

• Biologicals and HCT materials. The instrument treats biologicals as therapeutic goods composed of, containing or derived from human cells and human tissues termed HCT materials (defined in section 4). The standards differentiate between products that are subjected to only minimal manipulation and those that are not, and between autologous use and allogeneic use (section 4 definitions). These classifications determine which parts apply (see section 5 and specific Parts 3-7).

• General standard and specific standards. Part 2 contains general requirements that apply to all biologicals unless a specific provision in Parts 3-7 says otherwise (section 5 and repeated notes at the start of specific Parts). For example, the general requirement to take validated samples for bioburden testing (section 12) is expressly excluded for certain ocular products for which Part 5 sets bespoke requirements.

• Donor suitability and documented exceptions. Section 9 mandates that HCT materials must not be collected from donors known to have disease or conditions that may compromise product safety unless specified donor criteria and ineligibility periods based on validated data or literature are applied and documented, or a registered medical practitioner documents a medical rationale for use (section 9). The instrument therefore formalises both a risk‑based exclusion approach and a documented medical exception pathway.

• Critical materials and external guidance. Section 10 sets out rules for critical materials used in manufacture, requiring them to be free from contamination, to meet sterility or sterility‑equivalent manufacturing standards, and where of human or animal origin, to meet the TGA Approach to TSE and EMA Guidance on Virus Validation Studies. The Order distinguishes critical materials that appear on an unspecified Register from those that do not; for the latter, manufacturers must document screening tests and storage conditions (section 10(2)). The instrument therefore combines prescriptive requirements with a register‑based mechanism for specifying acceptable critical materials.

• Microbial control and bioburden testing. The instrument requires a risk‑based microbial contamination control strategy for HCT materials and biologicals (section 11). It mandates validated sampling techniques and validated test methods for bioburden sampling (section 12), and requires written specifications that include “specified microorganisms” determined by risk assessment (section 13). The product‑specific Parts then set out sampling timing, acceptable contamination outcomes and rejection criteria (for example, section 21 for musculoskeletal tissue, sections 27-28 for cardiovascular tissue, section 41 for skin, and section 35 for ocular corneal media).

• Time and temperature constraints, and validation. Throughout the instrument, timepoints (for example, collection windows after asystole, or time to cryopreservation) and temperature ranges are specified for storage, processing and transport. Many provisions provide a default requirement but permit alternative conditions that are validated by the manufacturer on the basis of validated data or documented literature (for example, sections 16(1)(a)(ii), 24(a)(iv), 30(1)(a)(ii), 34(d), 24(a)(iv), 43(2)(d) and 49(2)(c)). Validation is therefore a recurring obligation where deviation from the prescriptive norm is sought.

• Sterilisation assurance and terminal sterilisation. Section 14 requires that terminal sterilisation processes be validated to ensure a maximal sterility assurance level of 10^-6. Section 47 requires terminal sterilisation specifically for amnion products when the amnion was collected following vaginal delivery.

• Packaging and traceability. Section 17 requires sterile containers and at least double packaging that prevents ingress and egress and makes breaches of integrity evident. Numerous provisions require documentation of times (for example collection and processing times, storage intervals) and medical notifications for certain late collections (for example ocular tissue collected 24-48 hours after asystole under section 33(2)). These provisions create traceability and notification duties.

• Interaction with other documents. The Order expressly incorporates or references external guidance and standards (EBAANZ standards, TGA Approach to TSE, EMA guidance) without reproducing their content. Where the instrument defers to those documents, compliance requires accessing and applying the external material as it exists at the time (see section 4 references and section 10(1)(e)).

These concepts combine prescriptive limits (times, temperatures, sterility levels) with a structured, documented pathway to validation where a manufacturer proposes alternate conditions or needs an exception. That architecture shifts the operational burden onto manufacturers and sponsors to validate and document conformity or to apply the documented medical exception routes where the instrument provides them.

TGO 109 places obligations and creates compliance tasks for several clearly identified parties. The instrument’s language uses the terms manufacturer, sponsor and medical practitioner repeatedly; those actors and downstream stakeholders bear the direct costs and decision responsibilities.

• Manufacturers. The instrument primarily regulates activities that fall within the definition of manufacture and at manufacturing sites (see section 4 notes listing definitions in the Act). Manufacturers must implement quality management systems for critical materials (section 10(1)(c)), validate sterilisation and processing steps (sections 14, 21(3)(b)(ii) and others), conduct validated sampling and validated testing for bioburden (sections 12-13 and specific Parts), document storage and transport validation (sections 16 and product‑specific storage sections), package biologicals in sterile double packaging (section 17), maintain microbial contamination control strategies (section 11) and retain records that demonstrate conformity with the Order. Manufacturers also decide timing for processing where the Order permits validated alternatives and carry the burden of validation and documentation when departing from prescriptive conditions (many sections, e.g., 16(1)(a)(ii), 24(a)(iv)).

• Sponsors. The instrument references sponsors when authorisation by a registered medical practitioner acting for or on behalf of the manufacturer or the sponsor is required (section 9(b)). Sponsors who are responsible for supply and regulatory representation will therefore be implicated when a medical practitioner must document rationale for using materials that would otherwise be excluded.

• Medical practitioners. The Order assigns decision roles to registered medical practitioners in several places. First, where a donor has a disease or condition that may compromise a biological and validated exclusion criteria cannot be satisfied, a registered medical practitioner acting for or on behalf of the manufacturer or sponsor must agree and document rationale before the HCT materials may be used (section 9(b)). Second, Part 5 requires a medical practitioner to evaluate products made from ocular tissue collected between 24 and 48 hours after asystole and to notify the treating medical practitioner (section 33(2)(a)-(b)). Third, section 35(2)(b) requires reporting of contaminated corneal storage medium test results to the medical practitioner responsible for the recipient. These clauses make individual clinicians gatekeepers in narrowly specified exception and notification cases.

• Donors and donor families. The instrument places time and handling constraints on collection after asystole and requires documentation of intervals between asystole, enucleation, preservation and excision for ocular tissue (section 33(1)). While the Order is silent on consent mechanics, the timeframes and handling requirements will affect donor procurement operations and interaction with donor families, particularly where rapid collection or refrigeration windows apply.

• Tissue banks, eye banks and procurement services. Entities that collect, process, bank and distribute HCT materials will need to adjust collection schedules (sections 15, 20, 27, 33), adopt validated cold chain and packaging systems (sections 16 and 17), implement bioburden sampling programs (section 12), and meet specific product standards (for example, EBAANZ referenced in section 37). Eye banks, in particular, must follow the ocular tissue time and temperature regimes (Part 5) and test corneal storage media when certain storage temperatures are used (section 35).

• Clinical users (surgeons, hospitals). Clinical recipients and the clinicians responsible for administration may be notified in certain scenarios (section 33(2)(b), section 35(2)(b), section 41(2) reporting obligations). Clinicians will need to account for notification obligations where tissue was collected outside preferred windows or tests showed contamination with non‑specified microorganisms.

• Suppliers of critical materials and cold chain service providers. Suppliers that provide solutions, antimicrobial agents, or human/animal‑origin materials must meet the requirements in section 10, including manufacture under an approved quality management system and sterility requirements, and must support validation evidence where a manufacturer relies on them.

Who pays. Financially, the primary burden falls on manufacturers and sponsors: validation studies, additional sampling and testing, high‑integrity packaging and cold chain systems, documentation and record‑keeping, potential rejection and disposal of contaminated materials (multiple sections prescribe rejection on contamination), and engaging registered medical practitioners to authorise or evaluate exceptional cases (sections 9(b) and 33(2)). Tissue procurement organisations will face operational costs to meet collection timing and aseptic packaging obligations. Clinical users may face administrative costs from mandatory notifications and from accepting tissues that required medical‑practitioner evaluation when collections occurred late.

Who decides. The instrument assigns decision rights to manufacturers for operational validation and to registered medical practitioners for specific medical exceptions and evaluations. The TGA is the legislative source under the Act and will be the regulator responsible for enforcement under the Act’s enforcement mechanisms; the instrument itself does not set out new enforcement penalties.

TGO 109 creates a network of duties for manufacturers, sponsors, medical practitioners and related parties. The duties are primarily prescriptive and documentation‑oriented. The instrument does not create express novel rights such as private enforcement rights; it creates obligations that are enforceable under the Act’s regulatory framework.

Major duties

• Apply the appropriate standards. Manufacturers must determine which parts apply to a given biological (section 5 and the application provisions in Parts 3-7). Unless a specific part provides otherwise, Part 2’s general standard applies in addition to any specific part that applies.

• Donor selection and documentation. A biological must not be manufactured using HCT materials collected from a donor known to have a disease or condition that may compromise product safety unless validated donor criteria are applied and documented, or a registered medical practitioner documents and justifies use (section 9). Duty extends to defining criteria and ineligibility periods with validated data or literature.

• Control critical materials. Critical materials must not be contaminated or likely to introduce infectious agents, must not adversely affect the biological, and solutions that contact HCT materials must be supplied sterile or meet applicable sterility standards (section 10(1)(a)-(c)). Non‑sterile antimicrobial agents used in bioburden reduction must be filtered (section 10(1)(d)). Human or animal origin materials must meet TGA Approach to TSE and EMA guidance (section 10(1)(e)). If a critical material is not on the Register, manufacturers must document screening tests and storage conditions (section 10(2)).

• Implement contamination control and validation. Manufacturers must implement a risk‑based microbial contamination control strategy that specifies storage, handling and transportation requirements (section 11). Sampling for bioburden testing must use validated techniques and validated test methods (section 12). Written specifications must include specified microorganisms determined by risk assessment, and samples must demonstrate freedom from microbial contamination or, where risk assessment permits, freedom from specified microorganisms (section 13). For terminal sterilisation, processes must be validated to a sterility assurance level of 10^-6 (section 14).

• Timing and preservation duties. There are strict timing duties for collection from deceased donors (section 15, section 20, section 27(2)-28(2)), processing commencement windows (for skin and amnion at sections 40 and 46), and time limits for storage and cryopreservation (Parts 3-7). For example, human cardiovascular tissue not subjected to a bioburden reduction must be cryopreserved within 48 hours of asystole (section 27(2)(a)). These are duties with direct operational impact.

• Testing and rejection obligations. Tissue and products must be tested for bioburden at prescribed stages and rejected if contamination is demonstrated in the circumstances the Order prescribes (for instance, sections 21(2)(b)-(c), 27(3)-(4), 35(2)(a), 41(1)(b)).

• Packaging and transport. Biologicals must be sealed in sterile containers and at least double packaged (section 17). Storage and transport must be under validated conditions, with product‑specific temperatures and durations; a biological returned to a manufacturer cannot be released unless storage/transport met applicable requirements and labelling/packaging is intact (section 16(6)).

• Medical practitioner involvement. Where donor criteria cannot be met, a registered medical practitioner acting for or on behalf of the manufacturer or sponsor must agree and document the rationale (section 9(b)). For ocular tissue collected between 24 and 48 hours after asystole, a medical practitioner must evaluate the product and the treating clinician must be notified (section 33(2)).

Documentation and validation duties recur across the Order: validation studies, evidence or documented literature to justify alternative conditions, and documented procedures for labelling, packaging, and reporting test results are required in multiple places (sections 10(2), 11, 12(2), 13(1), 16(4), 24(a)(iv), 30(2)(b), 34(d), 43(2)(d), 49(2)(c), among others).

Rights and discretion

• Manufacturer discretion with validation. The Order grants manufacturers discretion to adopt alternative storage or processing conditions provided those are validated on the basis of validated data or documented evidence from relevant scientific literature (for example, sections 16(1)(a)(ii), 24(a)(iv), 30(1)(a)(ii)). That discretion is conditional on validation and documentation.

• Medical practitioner judgement. Registered medical practitioners have the right to authorise use of HCT materials in exceptional circumstances and to evaluate certain products collected out of preferred windows (sections 9(b) and 33(2)). This creates a formal role for clinical judgement within the regulatory framework.

• Register mechanism. The instrument contemplates a Register for critical materials; materials not on the Register carry different documentation duties (section 10(2)). The existence of a Register introduces a delegated choice mechanism but the Order itself does not set out the Register’s contents.

What the instrument does not do within its text

• The instrument contains no express new statutory offences or penalties. Enforcement must be pursued under the Therapeutic Goods Act 1989 and related Regulations; the Order itself is silent on penalties and enforcement mechanisms (see section 3 for the authority under the Act).

• It does not set out consent regimes, civil liabilities or clinical governance arrangements beyond requiring medical practitioner involvement in specified circumstances. It prescribes operational and documentation obligations rather than creating remunerative entitlements or private enforcement rights.

In short, the Order creates prescriptive manufacturing, collection, testing, storage, transport and packaging duties, combined with recurring documentation and validation obligations, while allocating clinical exception rights to registered medical practitioners.

The Order is a legislative instrument made under section 10 of the Therapeutic Goods Act 1989 (section 3). Its text sets standards and obligations but does not itself specify penalties, fines or criminal offences within the instrument. The instrument therefore operates as a subordinate standard that sits within the broader regulatory framework of the Therapeutic Goods Act and the Regulations (the instrument references the Regulations in section 4). Enforcement of the Order’s requirements will therefore be through the mechanisms and provisions available under the Act and the Regulations, rather than by penalties specified in the Order itself.

Consequences of non‑compliance

• Regulatory enforcement under the Act. Because the Order is made under the Act, contravention of the Order’s requirements can be relevant to regulatory action under the Act, including market authorisation, listing, registration, suspension, recall or other regulatory measures that the Therapeutic Goods Administration exercises under the Act and the Regulations. The instrument itself does not create new categories of criminal sanctions, nor does it amend the Act’s enforcement tools; it provides standards against which compliance may be judged.

• Administrative consequences. Non‑conformity with the standards in TGO 109 will be material to the TGA’s assessment of a manufacturer’s compliance with manufacturing standards and may expose manufacturing sites and sponsors to regulatory interventions available under the Act’s compliance regime, such as administrative notices, product recalls, or compliance directions. The Order’s repeated emphasis on validated processes, documentation and medical practitioner decisions creates documentary evidence that regulators will likely examine during inspections and reviews.

• Product removal and rejection. The Order contains specific rejection obligations. For instance, tissue that demonstrates microbial contamination when testing is required must be rejected for therapeutic use in specified circumstances (for example, sections 21(2)(b)-(c), 27(3), 28(4), 35(2)(a), 41(1)(b)). The practical consequence for non‑compliance with testing or contamination rules is product rejection and associated disposal or recall costs.

Reporting and notification duties

• Reporting obligations are embedded in some provisions. Where corneal storage medium tests demonstrate microbial contamination after a product has been released, the instrument requires reporting the results to the treating medical practitioner in accordance with documented manufacturer procedures (section 35(2)(b)). Where skin bioburden testing shows contamination with microorganisms other than specified microorganisms, manufacturers must report the test results to the medical practitioner responsible for the recipient (section 41(2)). These are operational notification duties that may have clinical and regulatory consequences.

Inspection and validation records

• The Order expects manufacturers to maintain validation evidence and documented procedures (for example, sections 10(2), 11, 12(2), 13(1)). Such records will be key evidence during TGA inspections. Failure to keep adequate records could impede a manufacturer’s ability to demonstrate compliance and thereby trigger enforcement action by the regulator.

Unspecified enforcement particulars

• The instrument does not set out enforcement thresholds, fine amounts or criminal offences. Where sanctions or penalties are sought, they will be drawn from the Act and Regulations. Practitioners and compliance officers must therefore consult the Therapeutic Goods Act and related regulations to map specific sanctions and enforcement processes to any breach of TGO 109 obligations.

In practice, enforcement will be a combination of: regulatory assessment and inspections by the TGA under the Act; administrative actions such as product suspension, recall or compliance notices; reputational consequences for manufacturers and sponsors; and the immediate commercial consequence of rejected, quarantined or recalled tissues where testing or packaging obligations are not met.

TGO 109 is formulated as a subordinate instrument under the Therapeutic Goods Act 1989 (section 3). Its content cross‑references other instruments, standards and guidance documents; its interaction with other legal and regulatory instruments should be viewed in two streams: (1) operation within the Act and regulatory ecosystem; and (2) reliance on external technical standards and prior TGOs.

Authority and statutory relationship

• Made under the Therapeutic Goods Act 1989. Section 3 states that the instrument is made under section 10 of the Act. As a Therapeutic Goods Order, it constitutes a standard for manufacturing biologicals. The Act and its Regulations establish offences, registration requirements and enforcement powers. TGO 109 sets standards to be met under that statutory power; the Act remains the primary legal framework for enforcement and compliance.

Cross‑references to the Regulations and definitions

• Definitions and terms. Section 4 notes that several expressions used in the instrument are defined in subsection 3(1) of the Act, including bioburden, biological, container, manufacture, manufacturing site, standard and supply. It also references the Therapeutic Goods Regulations 1990 (section 4). This means that interpretation of many terms requires consulting the Act and Regulations.

Interaction with former TGOs and transitional arrangements

• Transitional conformity option. Section 7 establishes that the former Therapeutic Goods Orders (Nos 83-86 and specified provisions of TGO 88) continue to apply as alternative standards during the transition period from 30 September 2021 to 30 September 2022. This creates an explicit legal bridge that allows manufacturers to comply with the prior Orders during the transition, avoiding immediate enforcement on the new Order alone for a period.

Delegation to external technical standards

• External guidance and standards are incorporated by reference. The instrument requires compliance with the EBAANZ Standards for Eye Donation and Eye Tissue Banking for ocular examination and evaluation (section 37), mandates that human or animal origin critical materials meet the TGA Approach to TSE and EMA Guidance on Virus Validation Studies (section 10(1)(e)), and references the Register for critical materials (section 10). These cross‑references mean that obligations under TGO 109 depend on the content of external documents. The instrument states that the external documents are to be applied as in force at the commencement or “as in force or existing from time to time” (section 4 references). Therefore, compliance requires monitoring those documents for updates.

Health and clinical regulatory regimes

• Medical practice regulation remains separate. The Order requires registered medical practitioners to document decisions or evaluate certain products (sections 9 and 33). Those clinicians remain subject to professional regulation under state and territory laws and their registration boards. The instrument requires clinicians to be registered in a State or internal territory for particular obligations (section 33(2)(c)), which suggests interface points with state registration and clinical practice regulation.

Other statutory regimes

• Transmissible spongiform encephalopathies and international guidance. The TGA Approach to TSE and the EMA Guidance on Virus Validation Studies are technical documents that have legal effect via TGO 109 for critical materials and virus validation requirements (section 10(1)(e)). This links the Order to public health and global regulatory standards in the areas of TSE and viral inactivation/removal.

Limitations and gaps

• The instrument does not replicate the Act’s enforcement provisions or civil liability rules. Any interaction with tort, consumer law, product liability regimes or criminal law arising from the manufacture or supply of biologicals remains governed by those regimes; the Order provides standards that may be evidence of reasonable practice in those contexts but does not, by itself, displace or modify those laws.

Practitioners must therefore treat TGO 109 as one component of a compliance matrix: it provides technical and procedural standards within the Act’s framework, references external technical documents for specialist content, and coexists with state and territory clinical regulation and general legal obligations such as product liability and professional standards.

The text of the instrument provided contains the original commencement and transitional statements and does not include subsequent amendment entries within the instrument itself. The instrument records the following original‑text metadata and transitional provisions:

• Commencement. The whole Order commenced on 30 September 2021 (section 2 and the commencement table). The instrument includes a note that the commencement table relates only to the instrument as originally made and will not be amended in the published instrument to deal with later amendments.

• Transitional arrangements. Section 7(1) defines “former instruments” to include Therapeutic Goods Orders Nos 83, 84, 85 and 86 (respectively: standards for human musculoskeletal tissue, cardiovascular tissue, ocular tissue and skin) as in force immediately before their repeal. It also defines “former provisions” as specific provisions of TGO 88. Section 7(2) states that despite the repeal of those former instruments and former provisions by the repeal instrument, they continue to apply for the transition period beginning 30 September 2021 and ending 30 September 2022, so that adherence to the former standards remains an alternative during that period.

• Note about the Register and referenced documents. The instrument references external documents and a Register (for critical materials) but does not set out those documents or the Register contents within the Order itself (sections 4 and 10). The EBAANZ standards and other referenced guidance are included by cross‑reference.

What is not in the instrument text

• No later amendments are recorded in the provided text. The instrument as provided does not contain any subsequent amendment notes, schedules, or amendment dates beyond the original commencement. The instrument explicitly notes that the commencement table relates only to provisions as originally made (section 2 note).

• No repeal or replacement beyond transition. The instrument records that the former TGOs were repealed by a repeal instrument, but it preserves their application during the transition period. The text does not show changes after the transition period.

Implications for compliance management

• During the transition period, manufacturers could choose to conform to the former Orders or to TGO 109. After the transition period, the former instruments cease to be an alternative. Compliance programmes must therefore be aware of timelines and of any actual subsequent amendments made outside this instrument’s text, by checking the Federal Register of Legislation for amendment history.

• If regulators or manufacturers have relied on the Register or the referenced external documents, any changes to those documents after commencement could change manufacturer obligations, because the instrument applies them “as in force or existing from time to time” where so stated (section 4 references and section 10(1)(e) language). Practitioners will need to monitor those external documents for changes.

For an authoritative, up‑to‑date amendment history, users must consult the Federal Register of Legislation or the TGA’s published instrument history, because the instrument as provided contains only the original commencement and transitional notes.

The instrument text provided does not include or cite any litigation, judicial interpretations or case law. The Order itself is a regulatory standard; litigation applying or interpreting it would arise only after its commencement and in the context of enforcement, administrative review or civil claims. The instrument makes no reference to decided cases, and no cases are named within the text.

Practical observations about litigation risk and likely dispute themes

• Disputes likely to focus on validation and reasonableness. Because TGO 109 gives manufacturers scope to validate alternative storage, processing and transport conditions (for example, sections 16(1)(a)(ii), 24(a)(iv), 30(1)(a)(ii), and others), disputes about compliance are likely to turn on the adequacy of validation evidence and documented procedures. Litigation or administrative disputes may therefore focus on whether validation studies were appropriately designed, executed and documented, and whether the evidence relied upon meets the Order’s requirement of “validated data or documented evidence from relevant scientific literature” (repeated across several sections).

• Bioburden testing and rejection decisions may be disputed. The instrument prescribes mandatory sampling, validated methods and rejection criteria for contamination in many places (for example, sections 12-13, 21, 27-28, 35, 41). Conflicts may arise where a manufacturer or sponsor elects to release a product after a borderline test result, or where clinical need pressures release of tissues that would otherwise be rejected. The Order’s documentation requirements will be central in any dispute about whether risk assessments and decisions were reasonable and compliant.

• Medical practitioner authorisations may be a focal point. Where a registered medical practitioner authorises the use of HCT materials that do not meet donor criteria, the sufficiency of the documented rationale and the scope of the clinical judgement applied may be scrutinised. Section 9(b) conditions such exceptions on the practitioner documenting rationale; disputes may arise about what is adequate documentation and whether the practitioner’s decision fell within clinical practice standards.

• Interplay with external documents. Because the Order references external standards (EBAANZ, TGA Approach to TSE, EMA guidance), disputes might examine whether a manufacturer followed those documents correctly. Determination of what the external guidance requires at a given time may be an evidentiary issue.

Absence of existing precedents in the instrument

• No cases named. The instrument contains no litigation history or named cases. Users looking for precedent on compliance questions must therefore look to decisions made under the Act, decisions about prior TGOs, and to administrative determinations or court cases that have applied related standards.

To summarise, the instrument itself contains no litigation history; likely litigation themes, if disputes emerge, will cluster around validation evidence, bioburden testing and rejection, and the sufficiency of documented clinical authorisations, all grounded in the text’s repeated validation and documentation demands.

TGO 109 contains many prescriptive and cross‑referencing provisions that can create practical traps for manufacturers, sponsors and procurers if not carefully mapped into company quality systems. The following are points where non‑obvious obligations, cross‑references or potential compliance pitfalls appear in the instrument.

1. Multiple overlapping standards and exemptions. Although Part 2 is a general standard, Parts 3-7 impose product‑specific requirements and frequently exclude or modify the general requirements. For example, section 12 requires validated sampling and testing for bioburden for all biologicals other than human ocular tissue products to which Part 5 applies, while Part 5 sets separate ocular rules (see section 12(2)-(3) and Part 5). Failure to map which provisions apply to a particular product can lead to applying incorrect sampling regimes.

2. Donor criteria versus medical practitioner exceptions. Section 9 requires exclusion of donors with diseases or conditions that may compromise biologicals unless validated donor selection criteria and ineligibility periods are applied and documented, or a registered medical practitioner acting for the manufacturer or sponsor documents the rationale for using the donor material (section 9(b)). The “medical practitioner exception” exists but is tightly couched as a documented exception, not a routine escape hatch. Manufacturers relying on this pathway must ensure the practitioner documents a clear rationale; otherwise, regulatory scrutiny could find the exception improperly used.

3. Register ambiguity for critical materials. Section 10 distinguishes critical materials that are included in “the Register” from those that are not. The instrument does not include the Register within its text. If manufacturers rely on a material presumed to be on the Register, they must confirm the Register’s current contents and ensure supporting documentation where a material is not listed. The absence of the Register in the instrument creates a potential documentary gap, and practitioners should verify register contents with the TGA.

4. Validation burden when deviating from prescriptive conditions. Many provisions allow alternative conditions if validated by the manufacturer (for example, alternative storage, transportation or processing windows in sections 16(1)(a)(ii), 24(a)(iv), 30(1)(a)(ii)). The instrument leaves the content and rigor of validation open but requires validation on the basis of validated data or documented literature. This places the evidentiary onus on manufacturers and may make ad hoc operational choices difficult to justify without structured validation studies.

5. Stringent timing for collection and processing. Collection timeframes for deceased donors are tight in places (for example, sections 15(1), 20(1)-(2), 27(2)-(3), 33(1)), and cryopreservation windows for cardiovascular tissue are stringent (section 27(2), 28(5)). Procurement organisations and donor coordinators must align logistics precisely. Unexpected delays or refrigeration timing differences can render tissue unusable or require medical practitioner evaluation for late collections (section 33(2)).

6. Sterility assurance standard for terminal sterilisation. Section 14 requires terminal sterilisation processes to be validated to a maximal sterility assurance level of 10^-6. This is a high benchmark and will typically require validated processes, substantial study data, and documentation. Not every facility will have validated terminal sterilisation capacity, and outsourcing or third‑party sterilisation must be validated and documented.

7. Product‑specific testing and rejection rules differ. For example, human musculoskeletal tissue subjected to processing can either be sampled after processing and must demonstrate no contamination, or be subjected to a validated bioburden reduction process to render it free from contamination (section 21(3)(b)). Other parts, like cardiovascular tissue, impose different sampling and processing time windows and temperatures (sections 27-28). Applying the wrong rule could lead to inadvertent release of non‑compliant material.

8. Packaging requirements and returns. Section 17 requires sterile containers and at least double packaging that evidences breaches. Section 16(6) bars releasing a returned biological unless it was at all times stored and transported according to requirements and labelling has not been compromised. The combination means that returned products face strict release gates that must be demonstrated in records , a logistical and administrative cost.

9. Notification obligations to clinicians. Where certain late collections occur for ocular tissue, manufacturers must ensure a medical practitioner evaluates the product and the treating clinician is notified (section 33(2)). Similarly, contaminated corneal storage medium test results must be reported to the treating clinician if the product has already been released (section 35(2)(b)). Manufacturers must embed notification workflows into their procedures or risk breaching the instrument’s reporting expectations.

10. Cross‑referenced external documents. Several technical obligations refer to documents outside the instrument (EBAANZ, TGA Approach to TSE, EMA guidance). Compliance requires obtaining, applying and monitoring updates to those documents. If manufacturers are unaware of changes in the external documents, they could inadvertently fall out of compliance.

11. Differences between autologous and allogeneic scopes. Several specific Parts apply only to products manufactured for allogeneic use (Parts 4 and 5 specify “manufactured for allogeneic use only”; see sections 26 and 32). Determining whether a product is autologous or allogeneic is therefore an essential gating decision that alters applicable requirements.

12. Residual moisture and residual calcium specifications. There are concrete, prescriptive limits that may affect processing methods and analytical testing , for example, residual calcium of demineralised musculoskeletal products not to exceed 8% w/w (section 22) and residual moisture for freeze‑dried musculoskeletal tissue not to exceed 6% w/w (section 23), skin freeze‑dried products less than 5% (section 42) and amnion dehydrated or freeze‑dried less than 15% (section 48). Ensuring analytical capability and validated assays to demonstrate compliance is necessary.

Collectively, these “gotchas” mean manufacturers must undertake a structured, mapped compliance analysis linking each product to specific provisions, identify where validation studies or external guidance apply, and implement documented procedures for decision pathways, especially where medical practitioners are required to sign off.

Compliance with TGO 109 requires a systematic implementation plan that maps each product to the relevant Parts (Part 2 plus one of Parts 3-7 as applicable), establishes validated processes, documents decisions and maintains records for regulatory inspection. The following is a practical compliance checklist grounded in the instrument’s text and should be adapted into a formal quality management plan.

1. Product classification and scoping

• Determine whether the product is a biological under the Act and whether it comprises, contains or is derived from HCT materials (section 4 definitions). Confirm whether the product has been subjected to only minimal manipulation; this determines whether Parts 3-7 apply.
• Identify whether the product is for autologous or allogeneic use, since Parts 4 and 5 apply only to products manufactured for allogeneic use (sections 26 and 32).

2. Apply Part 2 general requirements

• Implement a risk‑based microbial contamination control strategy that specifies storage, handling and transportation requirements including temperature and duration (section 11).
• Ensure critical materials meet the requirements in section 10: no contamination, no adverse effect on product, and sterile supply or compliance with applicable sterility requirements. For non‑sterile antimicrobial agents used in bioburden reduction, filter through 0.22μm prior to use (section 10(1)(d)).
• For critical materials not on the Register, document screening tests, quality control specifications and storage conditions (section 10(2)).

3. Sampling and testing

• Adopt validated sampling techniques and validated test methods for bioburden testing (section 12). For products where Part 5 applies, follow Part 5 testing rules; otherwise, follow section 12.
• Prepare written specifications that identify specified microorganisms as determined by a risk assessment (section 13(1)). Implement testing to demonstrate materials are free from contamination as required (sections 13(2)-(3)).

4. Sterilisation and validation

• If using terminal sterilisation, validate the process to demonstrate a sterility assurance level of 10^-6 (section 14). Maintain validation reports, routine monitoring and revalidation schedules.

5. Donor selection and documentation

• Define donor selection criteria and ineligibility periods supported by validated data or documented scientific literature (section 9(a)). Implement donor screening checklists incorporating these criteria.
• Where donor criteria cannot be met, obtain and document a registered medical practitioner’s agreement and rationale before using HCT materials (section 9(b)). Create a controlled workflow for medical practitioner exceptions including forms and evidence standards.

6. Collection timing and handling

• For deceased donors, ensure collection windows and completion times comply with the relevant Part (general rule in section 15 and product‑specific collection times in sections 20, 27 and 33). Record asystole times and refrigeration events to demonstrate compliance.
• Use aseptic technique and ensure packaging with at least one moisture impermeable barrier for HCT materials collected and transported for manufacture (section 16(3)).

7. Storage, transport and cold chain

• Apply product‑specific storage and transport conditions (for example, Part 3 section 24 for musculoskeletal tissue, Part 4 section 30 for cardiovascular tissue, Part 5 section 34 for ocular tissue, Part 6 section 43 for skin, Part 7 section 49 for amnion). Where the Order permits validated alternatives, maintain validation studies showing conditions prevent microbial proliferation and preserve product quality (numerous sections, e.g., 16(1)(a)(ii), 24(a)(iv)).
• Implement robust chain‑of‑custody records, temperature monitoring, alarmed transport systems and contingency procedures for excursions. Ensure returns are handled per section 16(6).

8. Packaging and labelling

• Package biologicals in sterile containers and ensure double packaging that prevents ingress and egress and makes integrity breaches evident (section 17). Create batch packaging checklists, tamper‑evident seals and inspection logs.

9. Product‑specific operational requirements

• For musculoskeletal tissue (Part 3): follow the collection time windows in section 20, bioburden sampling timing and rejection rules in section 21, and residual calcium and moisture limits for demineralised and freeze‑dried products in sections 22-23. Implement cryostorage rules in section 24 as applicable.
• For cardiovascular tissue (Part 4): determine whether tissue undergoes bioburden reduction; apply timing and antimicrobial exposure parameters in section 28, or follow section 27 for tissue not subjected to bioburden reduction. Ensure heart valves are competent before cryopreservation (section 29). Apply cryostorage at or below minus 100°C for cryopreserved products where required (section 30(2)).
• For ocular tissue (Part 5): perform collections within 48 hours and document intervals per section 33; follow storage options for cornea and excised cornea testing requirements in section 35; package to the requirements at section 36 and apply EBAANZ examination standards per section 37.
• For skin (Part 6): sample for bioburden after collection and before packaging (section 40), commence processing within 24 hours unless validated otherwise (section 40(2)), apply bioburden testing and notification rules in section 41, and meet freeze‑dry moisture limits (section 42). Observe storage windows in section 43.
• For amnion (Part 7): collect immediately after delivery and commence processing within 24 hours unless validated otherwise (section 46), terminally sterilise products from vaginal deliveries (section 47), meet moisture limits for dried products (section 48) and follow storage/transport rules (section 49).

10. Medical practitioner workflows

• Where the instrument requires a registered medical practitioner’s evaluation (for example, ocular tissue collected between 24 and 48 hours after asystole in section 33(2)) or agreement for exception (section 9(b)), implement forms, signature procedures and documentation retention aligned with professional registration requirements. Ensure the notifying clinician is registered in a State or internal territory as required (section 33(2)(c)).

11. Quality management system and records

• Ensure the QMS covers critical material sourcing, validation plans, sampling plans, sterility and bioburden testing, packaging, transport logs, exception handling, medical practitioner authorisations and reporting procedures. For critical materials, confirm that suppliers operate an approved QMS where required (section 10(1)(c)).
• Keep validation reports, batch records, test results, shipping temperature logs and rejection/destruction records. The instrument anticipates documentary evidence for inspections and for release decisions (e.g., sections 12, 16(6), 35(2)(b), 41(2)).

12. Transitional compliance

• During the transition period ending 30 September 2022, manufacturers may conform to the former Orders (sections 7(1)-(2)). Establish a plan to move from former TGO compliance to TGO 109 compliance before the transition expires, including gap analyses and validation projects.

13. Monitoring external documents and the Register

• Maintain an active monitoring process for external documents referenced by the Order (EBAANZ Standards, TGA Approach to TSE, EMA Guidance on Virus Validation Studies) because their applicable versions can affect compliance (section 4 and section 10(1)(e)). Confirm critical materials listed on the Register and maintain evidence if materials are not listed (section 10(2)).

14. Third‑party service providers and contracts

• Where sterilisation, cryostorage, transportation or testing is outsourced, ensure contracts require the third party to meet the Order’s standards and to provide validation evidence. Maintain records proving outsourced activities comply with specified temperature ranges, sterility assurance levels and validated methods.

15. Audit and inspection readiness

• Prepare for TGA inspection by ensuring all validation studies, test methods, sampling plans, donor‑selection criteria, medical practitioner exception documentation and shipping/packaging records are accessible. Develop corrective action plans for excursions and revalidation procedures.

This compliance checklist should be integrated into formal quality procedures, with responsibilities allocated to regulatory affairs, quality assurance, procurement, clinical liaison and manufacturing operations. The Order places validation, documentation and medical practitioner involvement at the centre of compliance; building those elements into SOPs and training is essential.